177Lu-OncoCAIX is a small molecule radiotracer with ultra high-affinity and specificity for Carbonic Anhydrase IX (CAIX).
CAIX is a validated target, which is not only expressed in the vast majority of Renal Cell Carcinoma (RCC), but also in other hypoxic tumors (e.g., a proportion of Colorectal Carcinoma and High-Grade Glioma).
The molecule consists of (i) a small organic ligand targeting CAIX, (ii) an innovative spacer structure and (iii) a DOTAGA chelator for the incorporation of 177Lutetium.
177Lu-OncoCAIX displays best-in-class performance both in vitro and in vivo with the highest reported selectivity to the CAIX antigen. In preclinical models of cancer, the product has shown a rapid and selective accumulation in the tumor mass with an extraordinarily low kidney uptake.
ONGOING CLINICAL TRIALS
- OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers
- Additional studies with OncoFAP-68Ga (Imaging) and OncoFAP-177Lu (Therapy) are about to start
